Liabilities for Sales of Future Royalties - Additional Information (Details) - USD ($) $ in Thousands |
1 Months Ended | 12 Months Ended | 49 Months Ended | |||
---|---|---|---|---|---|---|
Jul. 31, 2022 |
Dec. 31, 2019 |
Dec. 31, 2023 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Dec. 31, 2023 |
|
Liability For Sale Of Future Royalties [Line Items] | ||||||
Proceeds from the sale of future royalties, net | $ 0 | $ 490,950 | $ 0 | |||
Non-cash collaboration royalty revenue | $ 69,364 | 21,692 | $ 17,951 | |||
RPI Finance Trust (RPI) | ||||||
Liability For Sale Of Future Royalties [Line Items] | ||||||
Proceeds from the sale of future royalties, net | 0 | |||||
OMERS | ||||||
Liability For Sale Of Future Royalties [Line Items] | ||||||
Proceeds from the sale of future royalties, net | $ 490,950 | |||||
Royalty Purchase Agreement | ||||||
Liability For Sale Of Future Royalties [Line Items] | ||||||
Profit loss sharing percentage on net sales | 30.00% | |||||
Royalty Purchase Agreement | RPI Finance Trust (RPI) | ||||||
Liability For Sale Of Future Royalties [Line Items] | ||||||
Proceeds from sale of future royalties | $ 320,000 | |||||
Royalty payment termination description | The agreement with RPI will automatically terminate, and the payment of royalties to RPI will cease, in the event aggregate royalty payments received by RPI are equal to or greater than $608.0 million prior to December 31, 2030, or in the event aggregate royalty payments received by RPI are less than $608.0 million prior to December 31, 2030, or when aggregate royalty payments received by RPI are equal to $800.0 million. | |||||
Royalties transaction costs net | 5,800 | |||||
Proceeds from the sale of future royalties, net | 314,200 | |||||
Effective annual interest rate | 6.20% | 6.20% | ||||
Non-cash collaboration royalty revenue | $ 73,400 | |||||
Royalty Purchase Agreement | OMERS | ||||||
Liability For Sale Of Future Royalties [Line Items] | ||||||
Proceeds from sale of future royalties | $ 500,000 | |||||
Royalty payment termination description | In July 2022, the Company entered into a Royalty Purchase Agreement with OMERS. Pursuant to the agreement, OMERS paid $500.0 million to the Company in consideration for the right to receive 30% of the future royalty payments due to the Company from KKC based on net sales of Crysvita in the U.S. and Canada under the terms of the KKC Collaboration Agreement. The calculation of royalty payments to OMERS is based on net sales of Crysvita beginning in April 2023 and will expire upon the earlier of the date on which aggregate payments received by OMERS equals $725.0 million or the date the final royalty payment is made to the Company under the KKC Collaboration Agreement. | |||||
Royalty agreement termination threshold amount | $ 725,000 | |||||
Payment from sale of future royalties | 500,000 | |||||
Royalties transaction costs net | $ 9,100 | |||||
Proceeds from the sale of future royalties, net | $ 491,000 | |||||
Effective annual interest rate | 7.80% | 7.80% | ||||
Non-cash collaboration royalty revenue | $ 8,600 | |||||
Royalty Purchase Agreement | Minimum | RPI Finance Trust (RPI) | ||||||
Liability For Sale Of Future Royalties [Line Items] | ||||||
Royalty agreement termination threshold amount | $ 608,000 | 608,000 | ||||
Royalty Purchase Agreement | Maximum | RPI Finance Trust (RPI) | ||||||
Liability For Sale Of Future Royalties [Line Items] | ||||||
Royalty agreement termination threshold amount | $ 800,000 | $ 800,000 |